EQUITY ALERT: Rosen Law Firm Announces Filing of Securities

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Osiris Therapeutics, Inc. -- OSIR

NEW YORK, Dec. 22, 2015 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Osiris Therapeutics, Inc. (NASDAQ: OSIR ) securities from May 12, 2014 through November 20, 2015, all dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Osiris investors under the federal securities laws.

To join the Osiris class action, go to the firm’s website at http://rosenlegal.com/cases-786.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for more information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Osiris improperly recognized revenue under contracts it had with its distributors; (2) Osiris’ disclosure controls and procedures were not effective as of December 31, 2014, March 31, 2015, and June 30, 2015; and (3) as a result, defendants’ statements about Osiris’ business and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 22, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-786.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com .

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

CONTACT: Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 lrosen@rosenlegal.com pkim@rosenlegal.com kchan@rosenlegal.com www.rosenlegal.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Investors of Sage Therapeutics Have Chance to Join Lawsuit

Updated Category News Views 88

Introduction to the Class Action Lawsuit Attention, investors! There's an important opportunity arising for shareholder litigation against Sage Therapeutics, Inc. The legal firm Bronstein, Gewirtz & Grossman, LLC is officially notifying individuals who have invested in Sage Therapeutics about a class action lawsuit that has now been filed. If you have faced substantial...

Continue Reading
FARO Technologies Revolutionizes 3D Metrology with Leap ST

Updated Category News Views 105

FARO Technologies Enhances 3D Metrology with Leap ST FARO Technologies, Inc. (NASDAQ: FARO) is pushing the boundaries of handheld scanning technology with the introduction of the Leap ST. This launch marks a significant expansion of FARO's product portfolio, positioning the company among the few firms offering a comprehensive range of portable 3D metrology solutions. Leap...

Continue Reading
Strong Financial Performance and Growth Strategies at TORM PLC

Updated Category News Views 181

TORM PLC Reports Robust Q3 2025 Financial Results TORM PLC has demonstrated remarkable resilience and adaptability, reporting its strongest quarterly results in 2025. This achievement underscores the effectiveness of TORM's integrated operating model, as highlighted by the CEO. The company continues to prioritize creating long-term value for its shareholders while...

Continue Reading
Manhattan Associates Faces Legal Challenges Amid Shareholder Losses

Updated Category News Views 304

Manhattan Associates Faces Legal Challenges Following Shareholder Loss In recent developments, Manhattan Associates, Inc. (NASDAQ: MANH) is under scrutiny as a class action lawsuit has been filed against the company. This action comes after an alarming drop in shareholder value, amounting to over $4 billion. The lawsuit is pivotal as it involves allegations of misleading...

Continue Reading
BioLife Solutions Announces Upcoming Financial Results

Updated Category News Views 91

BioLife Solutions to Share Key Financial Insights BioLife Solutions, Inc. (NASDAQ: BLFS), a pioneering developer and supplier of bioproduction products and services specializing in cell and gene therapies, is gearing up for a significant event. The company plans to release its financial results for the third quarter of 2024 after market hours on November 12, 2024. This is...

Continue Reading